Fintel reports that on Nov 17, 2023, Truist Securities initiated coverage of Curis (NASDAQ:CRIS) with to buy recommendation
Analysis Price Forecast Suggests 1,673.35% Up
As of November 1, 2023, the average one-year price target for Curis is 104.80. The forecasts range from a low of 51.51 to a high of $210.00. The average price target represents an increase of 1,673.35% from its last reported closing price of 5.91.
See our leaderboard of companies with the largest price target.
The projected annual revenue for Curis is 11MM, an increase of 8.97%. The projected annual non-GAAP EPS is -0.45.
What is the Basic Sense?
There are 24 funds or institutions reporting positions in Curis. This is a decrease of 60 owner(s) or 71.43% in the last quarter. Average portfolio weight of all funds dedicated to CRIS is 0.00%, a decrease of 95.76%. Total shares owned by institutions decreased in the last three months by 85.19% to 4,522K shares. CRIS’s put/call ratio is 0.00, indicating a bullish outlook.
What Are Other Shareholders Doing?
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 2,183K shares representing 37.11% ownership of the company. In its previous filing, the company reported owning 1,853K shares, representing an increase of 15.14%. The company increased its portfolio allocation in CRIS by 51.41% during the last quarter.
VEXMX – Vanguard Extended Market Index Fund Investor Shares holds 1,054K shares representing 17.92% ownership of the company. No change in the last quarter.
FSMAX – Fidelity Extended Market Index Fund holds 486K shares representing 8.26% ownership of the company. In its previous filing, the company reported owning 413K shares, representing an increase of 15.13%. The company decreased its portfolio allocation in CRIS by 23.18% during the last quarter.
BRSIX – Ultra-Small Company Market Fund Class N holds 240K shares representing 4.08% ownership of the company. No change in the last quarter.
Dimension Capital Management holds 210K shares representing 3.57% ownership of the company. In its previous filing, the company reported owning 130K shares, representing an increase of 38.10%. The company increased its portfolio allocation in CRIS by 52.33% during the last quarter.
Curis Background Information
(This description is provided by the company.)
Curis is a biotechnology company focused on the development of innovative therapies for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948 . CA-4948 is currently undergoing Phase 1 testing in patients with non-Hodgkin lymphoma both as monotherapy and in combination with the BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche commercialize Erivedge® for the treatment of advanced basal cell carcinoma.
Fintel is one of the most comprehensive investment research platforms available for individual investors, traders, financial advisors and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fundamental sentiment, option sentiment, insider trading, option flow, unusual options trades and much more. Additionally, our exclusive stock options are powered by advanced, back-tested quantitative models for enhanced returns.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.